Dr. Boorjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511Fax+1 507-284-0161
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 2002 - 2006
- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2000 - 2002
- Harvard Medical SchoolClass of 2000
Certifications & Licensure
- IA State Medical License 2022 - 2026
- IL State Medical License 2022 - 2026
- ND State Medical License 2022 - 2026
- MN State Medical License 2010 - 2025
- WI State Medical License 2022 - 2025
- PA State Medical License 2008 - 2010
- NY State Medical License 2001 - 2009
- American Board of Urology Urology
Awards, Honors, & Recognition
- Young Urologist of the Year American Urological Association, 2014
- AUA-EAU Academic Exchange Program Scholar 2014
- Teacher of the Year Department of Urology, Mayo Clinic Fellows' Association, 2012
- Join now to see all
Clinical Trials
- ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Start of enrollment: 2016 Sep 19
- Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer Start of enrollment: 2019 Sep 03
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 25 citationsHigh grade neuroendocrine carcinoma of the urinary bladder treated by radical cystectomy: a series of small cell, mixed neuroendocrine and large cell neuroendocrine ca...Sounak Gupta, R. Houston Thompson, Stephen A. Boorjian, Prabin Thapa, Loren P. Herrera Hernandez
Pathology. 2015-10-01 - 95 citationsAssessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical ProstatectomyNicola Fossati, R. Jeffrey Karnes, Cesare Cozzarini, Claudio Fiorino, Giorgio Gandaglia
European Urology. 2016-04-01 - 167 citationsIncreased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the BladderJay D. Raman, Nigel P. Mongan, Satish K. Tickoo, Stephen A. Boorjian, Douglas S. Scherr
Clinical Cancer Research. 2005-12-15
Journal Articles
- Radical Versus Partial Nephrectomy for cT1 Renal Cell CarcinomaBoris Gershman, Stephen A Boorjian, Bradley C Leibovich, European Urology
- The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and TreatmentBimal Bhindi, Igor Frank, Aaron M Potretzke, Stephen A Boorjian, John C Cheville, Bradley C Leibovich, European Urology
- Temporal Trends in Venous Thromboembolism After Radical Cystectomy☆Matthew K Tollefson, Igor Frank, Stephen A Boorjian, Urologic Oncology
Authored Content
- A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous CohortsMay 2018
- Predicting Oncologic Outcomes in Renal Cell Carcinoma After SurgeryFebruary 2018
- Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-Term Results from a Large, Multi-Institutional SeriesDecember 2017
Press Mentions
- FDA Approves First Gene Therapy for Non-Muscle-Invasive Bladder CancerDecember 16th, 2022
- Clinical Trials for Bladder CancerSeptember 3rd, 2022
- Clinical Trials for Bladder CancerSeptember 1st, 2022
- Join now to see all
Committees
- Member, National Comprehensive Cancer Network Guideline Panel: Bladder Cancer/Penile Cancer 2014 - Present
Professional Memberships
- Member
- Member
- Society of Urologic OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: